Neuroscience
From Reuters:
Abbott Says Withdrawing Attention Deficit Drug
24 March 2005
Health - Reuters
WASHINGTON (Reuters) - Abbott Laboratories Inc. said Thursday it was halting sales of a 30-year-old attention deficit drug that a consumer group complained was too dangerous to stay on the market.
Abbott decided to discontinue the drug, Cylert, because of declining sales, Abbott spokeswoman Melissa Brotz said. The drug's sales this year will be less than $1 million, she said.
[ ... Read the full article ... ]
- Modafinil, Adhd, And The Fda
From The Washington Post: Use of Drug to Treat ADHD in Children Opposed Associated Press Friday, March 24, 2006; Page A11 The narcolepsy drug modafinil should not be approved as a treatment for attention-deficit hyperactivity disorder in children until...
- Methylphenidate Transdermal Patch (daytrana), Adhd, & The Fda: Thursday And Friday
THURSDAY: From The Washington Post website:Problem Found With Potential ADHD Patch The Associated Press Thursday, December 1, 2005; 3:01 PM WASHINGTON -- A patch developed to treat attention deficit hyperactivity disorder in children received a negative...
- Business World: Takeda's Ramelteon (tak-375)
A Reuters report:Takeda may extend sleeping pill's use for Alzheimer's Mon Jul 11, 2005 05:41 AM ET TOKYO, July 11 (Reuters) - Japan's biggest drug maker, Takeda Pharmaceutical Co. Ltd ... said on Monday it is on track to release a sleeping...
- More M.s. Drug Woes: Avonex And 683699
Biogen and F.D.A. Issue Drug Warning By ANDREW POLLACK The New York Times Published: March 17, 2005 Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said...
- Tysabri (natalizumab): An Additional Case
Rare Infection Is Confirmed in 2nd Patient on M.S. Drug By ANDREW POLLACK The New York Times Published: March 4, 2005 The makers of the multiple sclerosis drug Tysabri said yesterday that a second patient who used the drug had been confirmed to be suffering...
Neuroscience
Cylert
From Reuters:
Abbott Says Withdrawing Attention Deficit Drug
24 March 2005
Health - Reuters
WASHINGTON (Reuters) - Abbott Laboratories Inc. said Thursday it was halting sales of a 30-year-old attention deficit drug that a consumer group complained was too dangerous to stay on the market.
Abbott decided to discontinue the drug, Cylert, because of declining sales, Abbott spokeswoman Melissa Brotz said. The drug's sales this year will be less than $1 million, she said.
[ ... Read the full article ... ]
- Modafinil, Adhd, And The Fda
From The Washington Post: Use of Drug to Treat ADHD in Children Opposed Associated Press Friday, March 24, 2006; Page A11 The narcolepsy drug modafinil should not be approved as a treatment for attention-deficit hyperactivity disorder in children until...
- Methylphenidate Transdermal Patch (daytrana), Adhd, & The Fda: Thursday And Friday
THURSDAY: From The Washington Post website:Problem Found With Potential ADHD Patch The Associated Press Thursday, December 1, 2005; 3:01 PM WASHINGTON -- A patch developed to treat attention deficit hyperactivity disorder in children received a negative...
- Business World: Takeda's Ramelteon (tak-375)
A Reuters report:Takeda may extend sleeping pill's use for Alzheimer's Mon Jul 11, 2005 05:41 AM ET TOKYO, July 11 (Reuters) - Japan's biggest drug maker, Takeda Pharmaceutical Co. Ltd ... said on Monday it is on track to release a sleeping...
- More M.s. Drug Woes: Avonex And 683699
Biogen and F.D.A. Issue Drug Warning By ANDREW POLLACK The New York Times Published: March 17, 2005 Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said...
- Tysabri (natalizumab): An Additional Case
Rare Infection Is Confirmed in 2nd Patient on M.S. Drug By ANDREW POLLACK The New York Times Published: March 4, 2005 The makers of the multiple sclerosis drug Tysabri said yesterday that a second patient who used the drug had been confirmed to be suffering...